Get the Stockscreener App
0.00
100.00%
-29.08
After Hours:
29.30
29.30
+
Mersana Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$29.08
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$145.36M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
0.00
EPS:
-8.0157
Net Cash Flow:
$-79.76M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$30.39
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.00 | 145.36M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
Setup Watch: How is Mersana Therapeutics Inc. managing supply chain issues2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can Mersana Therapeutics Inc. (0M4) stock double in coming years2026 Big Picture & Detailed Earnings Play Strategies - Naître et grandir
Is Mersana Therapeutics Inc. stock a smart buy before Fed meetingGap Up & Low Risk Investment Opportunities - Naître et grandir
Aug Patterns: Is Mersana Therapeutics Inc a top pick in the sectorJuly 2025 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Guidance Update: Does Mersana Therapeutics Inc have pricing powerWeekly Trend Summary & AI Enhanced Trading Signals - baoquankhu1.vn
MRSN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Day One Weighs OJEMDA Momentum Against Expanded Oncology Pipeline Risks - Sahm
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead (NASDAQ:DAWN) - Seeking Alpha
Day One Highlights Transformational 2025 and OJEMDA Growth - TipRanks
Cancer drug OJEMDA powers Day One’s $155M year, bigger 2026 sales target set - Stock Titan
Day One Biopharmaceuticals earnings up next after Mersana deal - Investing.com Australia
Day One Biopharmaceuticals earnings up next after Mersana deal By Investing.com - Investing.com Canada
Market Outlook: Is Mersana Therapeutics Inc benefiting from interest rate changesJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
How Mersana Therapeutics Inc. stock performs in weak economyJuly 2025 Setups & Daily Profit Focused Screening - mfd.ru
Resistance Check: How is Mersana Therapeutics Inc managing supply chain issuesTrade Analysis Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Growth Report: Can Mersana Therapeutics Inc. stock sustain revenue growth2025 Fundamental Recap & AI Forecasted Entry and Exit Points - mfd.ru
Published on: 2026-02-14 07:10:10 - mfd.ru
Is Mersana Therapeutics Inc. forming a bullish divergenceMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru
Can Mersana Therapeutics Inc. withstand a market correctionEarnings Growth Summary & Weekly High Conviction Trade Ideas - mfd.ru
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 - GlobeNewswire
Day One Biopharma to review Q4 and 2025 results in Feb. 24 webcast - Stock Titan
Is Mersana Therapeutics Inc a top pick in the sectorJuly 2025 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Aug Sentiment: What are Mersana Therapeutics Incs recent SEC filings showing2025 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Gap Down: Is Rockwell Automation Inc stock good for income investorsJuly 2025 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Weekly Trades: What is the next catalyst for The Marygold Companies Inc2025 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Income Plays: How analysts rate Mersana Therapeutics Inc stock today2025 Geopolitical Influence & Fast Momentum Entry Tips - Bộ Nội Vụ
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Sees Large Drop in Short Interest - MarketBeat
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - The Manila Times
Day One Biopharmaceuticals Reports 172% Year-over-Year Growth in 2025 Net Product Revenue, Projects 2026 Revenue Between $225 Million and $250 Million - Quiver Quantitative
Cancer drug OJEMDA sales jump 172% in 2025 as Day One sets 2026 target - Stock Titan
Is Mersana Therapeutics Inc. stock positioned for long term growthJuly 2025 Action & AI Forecast for Swing Trade Picks - Улправда
Day One Biopharmaceuticals Stock Pre-Market (+5.4%) : Market Digests Mersana Acquisition - Trefis
Mersana Therapeutics (NASDAQ:MRSN) Upgraded at Wall Street Zen - MarketBeat
Is Mersana Therapeutics Inc. stock a buy on dipsWeekly Profit Report & Risk Controlled Swing Alerts - Улправда
Will Mersana Therapeutics Inc. stock maintain growth storyWeekly Trade Report & Fast Gain Stock Tips - Улправда
Published on: 2026-01-09 13:08:50 - Улправда
Is Mersana Therapeutics Inc. stock a buy before product launches2025 Technical Overview & AI Powered Trade Plan Recommendations - Улправда
Free cash flow of Mersana Therapeutics, Inc. – LSX:A41BV2 - TradingView — Track All Markets
How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance
Day One concludes Mersana Therapeutics acquisition - Yahoo Finance
Mersana Therapeutics, Inc.Common Stock (NQ: MRSN - FinancialContent
Mersana Therapeutics Completes Merger and Delists from Nasdaq - The Globe and Mail
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Mersana Therapeutics Announces Board and Management Changes Following Merger - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - The Manila Times
Day One buys Mersana to advance drug for rare salivary cancer - Stock Titan
Mersana Therapeutics, Inc.(NasdaqGS: MRSN) dropped from S&P TMI Index - marketscreener.com
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):